Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aclaris Therapeutics, Inc. Director's Dealing 2021

Mar 4, 2021

33670_dirs_2021-03-03_bc52ef14-62b9-4682-9a27-a128882281f2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2021-03-01

Reporting Person: Ruffo Frank (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-03-01 Common Stock M 25750 Acquired 240939 Direct
2021-03-01 Common Stock F 7333 $24.06 Disposed 233606 Direct
2021-03-02 Common Stock M 8297 Acquired 241903 Direct
2021-03-02 Common Stock F 2844 $23.25 Disposed 239059 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-03-01 Employee Stock Option (Right to Buy) $24.06 A 116000 Acquired 2031-02-28 Common Stock (116000) Direct
2021-03-01 Restricted stock units $ A 33200 Acquired Common Stock (33200) Direct
2021-03-01 Restricted stock units $ M 25750 Disposed Common Stock (25750) Direct
2021-03-02 Restricted stock units $ M 8297 Disposed Common Stock (8297) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

F3: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date.

F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F5: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F6: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.